MMV609

MMV609

Translational
-
Preclinical
University of Kentucky
Asexual blood stages
Transmission reduction
Product vision
  • Uncomplicated malaria treatment
MOA
  • PfATP4
Key features
  • Fast-acting against all species
  • Predicted 40 mg single-dose
  • Transmission-blocking activity
Challenges
  • High resistance risk (including G358S mutant)
  • Same MoA as phase II compounds: cipargamin and SJ733
  • Synthetic route optimization and cost of goods
  • Limited solubility
Status
  • Preclinical development
Next milestone
  • Synthetic route optimization
  • Start Good Laboratory Practice toxicology program
Previously
  • Discovery collaboration with Kip Guy (University of Kentucky)
  • MMV609; Full reference MMV1793609
Project Director
  • Dr Benoît Bestgen